In BRAF/ KRAS mutant NSCLC, PKCα was shown to modulate sensitivity to chemotherapy via mediating MDR1 expression and RLIP76 phosphorylation (Figure 4) [40,41,42]. Here, KRAS is linked to non-small cell lung carcinoma.